Barter Z[au] - Search Results

Year	Number of Results
2007	2
2008	1
2010	1
2011	3
2013	5
2014	2
2016	1
2021	1
2023	2
2024	0

1

Development and application of a PBPK modeling strategy to support antimalarial drug development.

Abla N, Howgate E, Rowland-Yeo K, Dickins M, Bergagnini-Kolev MC, Chen KF, McFeely S, Bonner JJ, Santos LGA, Gobeau N, Burt H, Barter Z, Jones HM, Wesche D, Charman SA, Möhrle JJ, Burrows JN, Almond LM. Abla N, et al. Among authors: barter z. CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1335-1346. doi: 10.1002/psp4.13013. Epub 2023 Aug 16. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37587640 Free PMC article.

2

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A. Barter ZE, et al. Curr Drug Metab. 2007 Jan;8(1):33-45. doi: 10.2174/138920007779315053. Curr Drug Metab. 2007. PMID: 17266522 Review.

3

Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.

Chen G, Sun K, Michon I, Barter Z, Neuhoff S, Ghosh L, Ilic K, Song IH. Chen G, et al. Among authors: barter z. J Clin Pharmacol. 2023 Nov 27. doi: 10.1002/jcph.2385. Online ahead of print. J Clin Pharmacol. 2023. PMID: 38009271

4

Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.

Sun L, Barter Z, von Moltke L, Rowland Yeo K. Sun L, et al. Among authors: barter z. CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1071-1080. doi: 10.1002/psp4.12675. Epub 2021 Jul 18. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34185436 Free PMC article.

5

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A. Neuhoff S, et al. Among authors: barter z. J Pharm Sci. 2013 Sep;102(9):3145-60. doi: 10.1002/jps.23594. Epub 2013 May 22. J Pharm Sci. 2013. PMID: 23703021

6

Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes.

Perrett HF, Barter ZE, Jones BC, Yamazaki H, Tucker GT, Rostami-Hodjegan A. Perrett HF, et al. Among authors: barter ze. Drug Metab Dispos. 2007 Oct;35(10):1733-6. doi: 10.1124/dmd.107.015743. Epub 2007 Jun 28. Drug Metab Dispos. 2007. PMID: 17600083

7

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A. Neuhoff S, et al. Among authors: barter z. J Pharm Sci. 2013 Sep;102(9):3161-73. doi: 10.1002/jps.23607. Epub 2013 May 19. J Pharm Sci. 2013. PMID: 23686764

8

Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan A. Salem F, et al. Among authors: barter ze. J Clin Pharmacol. 2013 Aug;53(8):857-65. doi: 10.1002/jcph.100. Epub 2013 May 30. J Clin Pharmacol. 2013. PMID: 23720017

9

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6.

Ke A, Barter Z, Rowland-Yeo K, Almond L. Ke A, et al. Among authors: barter z. CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):367-76. doi: 10.1002/psp4.12088. Epub 2016 Jul 20. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27435752 Free PMC article.

10

Response to "Ethnic-specific in vitro-in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in Chinese population: opportunities and challenges".

Barter ZE, Tucker GT, Rowland-Yeo K. Barter ZE, et al. Clin Pharmacokinet. 2014 Feb;53(2):203. doi: 10.1007/s40262-013-0118-x. Clin Pharmacokinet. 2014. PMID: 24255012 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

18 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year